Small Caps | 11:00 AM
A US blood-supply crisis, incumbent technology being phased out and encouraging clinical validation are combining to strengthen the outlook for Vitrafy Life Sciences
- Exciting times for Vitrafy Life Sciences’ blood technology
- Tailwinds include blood crisis and old tech phase out
- Milestones already met and anticipated
- Bell Potter sees a FY27 inflection point
By Mark Woodruff
For only the second time in its 150-year history, the American Red Cross, which supplies around 40% of US blood products, declared a national blood supply crisis in late July.
Type O-positive inventories had fallen below one day’s supply, highlighting the structural vulnerability of the US blood supply chain.
Against a backdrop highlighting the need for greater blood-supply resilience, biomedical technology company Vitrafy Life Sciences ((VFY)) is preparing to launch technology that could transform blood from a highly perishable product into a stable inventory asset through cryopreservation.
At the same time, the company’s proprietary technology could replace ageing incumbent systems as they are progressively phased out.
Aiming to improve the consistency and quality of preserved biological materials, cryopreservation involves the freezing, storage, transport and eventual thawing of biological materials.
Applications span cell and gene therapies, blood products and animal reproduction.
The Vitrafy business combines hardware, software and data into an integrated cryopreservation ecosystem.
At the core of the ecosystem is Guardion, the company’s controlled-rate freezing platform.
A potential turning point for Vitrafy
A rising share price has provided an early reward for patient shareholders, yet Bell Potter believes FY27 could deliver the real inflection point.
Successful FDA registration and inaugural commercial contracts have the potential to materially lift value, particularly as problems confronting the US blood sector create what the broker sees as a potentially transformational opportunity.
While cautioning commercial success is far from assured, Morgans, which initiated research coverage last week, assesses strong scientific data, a forced US blood-sector re-equipment cycle and a funded runway as providing Vitrafy with a credible opportunity to become the replacement standard for US frozen blood infrastructure.
Cell and gene therapy (CGT) and animal reproduction are seen as providing additional upside.
Similarly upbeat, Ord Minnett expects further US blood collection partnerships in FY27, noting additional agreements with a relatively small group of blood collection organisations --American Red Cross (22% market share), OneBlood (9%), LifeSouth (6%) and Versiti (5%)-- could lift Vitrafy’s market coverage above 50%, from around 13% currently through Vitalant and Hoxworth.
Management's targets and execution
Management is pursuing a US land-and-expand strategy, using military validation through the US Army Institute of Surgical Research (USAISR) to open doors with civilian blood networks, Morgans explains.
The USAISR is the US military’s principal research organisation focused on improving survival and recovery from combat injuries.
In external validation, Morgans highlights May 2026 platelet data as a step change rather than an incremental improvement. The Phase II USAISR study achieved 94.4% post-thaw platelet recovery using a 3% DMSO no-wash protocol, exceeding both FDA and European standards.
Importantly, there is currently no FDA-approved no-wash frozen platelet product commercially available in the US.
Morgans considers the study’s independent authorship by the USAISR adds credibility that a company-funded study would not carry.
It’s believed the next step is to leverage those relationships as a potential pathway into cell and gene therapy (CGT), where blood centres form part of the raw material supply chain.
Key milestones still pending include FDA registration, targeted before end-2026, conversion of blood network pilots into paid or exclusive deployments, and disclosure of commercial terms in CGT.
Milestones achieved during FY26 included completion of Phase II USAISR testing, agreements with IMV, Vitalant and Hoxworth, delivery of the first Guardion units, and the appointment of Brent Owens as CEO from September 2025.
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE